Immunosuppressant Therapeutic Drug Monitoring Tests – Medical Devices Pipeline Assessment, 2020

Immunosuppressant Therapeutic Drug Monitoring are the reagents used for the detection of immunosuppressant concentration in human body are covered under immunosuppressant TDM surgical devices that are used to make a tiny incision in the areas to be operated. GlobalData's Medical Devices sector report, “Immunosuppressant Therapeutic Drug Monitoring Tests – Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Immunosuppressant Therapeutic Drug Monitoring Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Immunosuppressant Therapeutic Drug Monitoring Tests Pipeline Assessment report provides key information and data related to:

Extensive coverage of the Immunosuppressant Therapeutic Drug Monitoring Tests under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Immunosuppressant Therapeutic Drug Monitoring Tests pipeline products.

Review of Recent Developments in the segment / industry

The Immunosuppressant Therapeutic Drug Monitoring Tests Pipeline Assessment report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Glaucoma Drainage Device sunder development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

The major companies covered in the “Immunosuppressant Therapeutic Drug Monitoring Tests- Medical Devices Pipeline Assessment, 2020” report:

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025

• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports

• 64,000+ medical equipment company profiles

• 5,600+ company profiles of medical equipment manufacturers in China and India

• 2,200+ company profiles of medical equipment manufacturers in Japan

• 1,200+ companies’ revenue splits and market shares

• 1,600+ quarterly and annual medical equipment company financials

• 850+ medical equipment company SWOTs

• 28,000+ pipeline product profiles

• 56,400+ marketed product profiles

• 47,000+ clinical trials

• 41,500+ trial investigators

• 7,000+ reports on companies with products in development

• 44,000+ deals in the medical equipment industry

• 1,100+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

• 431,000+ Themes Content Items

• 600+ Influencers

• 1,900+ Analysts & Researchers

• 0.5m+ Community Members

• 141,000+ Macroeconomic Indicators

• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

Extensive coverage of the Immunosuppressant Therapeutic Drug Monitoring Tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Immunosuppressant Therapeutic Drug Monitoring Tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to:

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Immunosuppressant Therapeutic Drug Monitoring Tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product’s current stage of development, territory and estimated launch date

Companies mentioned

BIOHOPE Scientific SL

Laboratory Corp of America Holdings

Ortho-Clinical Diagnostics Inc

Progenika Biopharma SA

Roche Diagnostics International Ltd

Siemens Healthcare Diagnostics Inc

Thermo Fisher Scientific Inc

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 5

2 Introduction 6

2.1 Immunosuppressant Therapeutic Drug Monitoring Overview 6

3 Products under Development 7

3.1 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Stage of Development 7

3.2 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Territory 8

3.3 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Regulatory Path 9

3.4 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Estimated Approval Date 10

4 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products under Development by Companies 11

4.1 Immunosuppressant Therapeutic Drug Monitoring Companies – Pipeline Products by Stage of Development 11

4.2 Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Stage of Development 12

5 Immunosuppressant Therapeutic Drug Monitoring Companies and Product Overview 14

5.1 BIOHOPE Scientific SL Company Overview 14

5.1.1 BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview 14

5.2 Laboratory Corp of America Holdings Company Overview 15

5.2.1 Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 15

5.3 Ortho-Clinical Diagnostics Inc Company Overview 17

5.3.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.4 Progenika Biopharma SA Company Overview 21

5.4.1 Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Roche Diagnostics International Ltd Company Overview 22

5.5.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 Siemens Healthcare Diagnostics Inc Company Overview 38

5.6.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.7 Thermo Fisher Scientific Inc Company Overview 46

5.7.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 46

6 Immunosuppressant Therapeutic Drug Monitoring- Recent Developments 47

6.1 Jul 13, 2020: Thermo Fisher Scientific and first genetics JCS partner to develop next-generation sequencing-based diagnostics in Russia 47

6.2 Jun 09, 2020: Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities 47

6.3 May 14, 2020: Aurinia reports first quarter 2020 financial results and recent operational highlights 48

6.4 Mar 09, 2020: THERADIAG announces the CE Marking for the first four i-Tracker Test Kits in its TRACKER Range 50

6.5 Mar 05, 2020: Aurinia reports fourth quarter and full year 2019 financial results and operational highlights 51

6.6 Feb 26, 2020: Thermo Fisher Scientific President and Chief Executive Officer Marc N. Casper elected Chairman of the Board of Directors 55

6.7 Feb 25, 2020: Aurinia appoints Max Colao as Chief Commercial Officer and expands U.S. commercial leadership team 55

6.8 Feb 04, 2020: Waters reports fourth quarter and full-year 2019 financial results 57

6.9 Feb 03, 2020: Siemens Healthineers starts new fiscal year with strong growth – outlook confirmed 58

6.10 Jan 30, 2020: Thermo Fisher Scientific reports fourth quarter and full year 2019 results 60

6.11 Jan 30, 2020: Theradiag reports 2019 revenue of €9.6 million, Up

8.3% 63

6.12 Jan 02, 2020: Agilent expands cross-vendor CDS instrument control 64

6.13 Dec 11, 2019: Biohope receives ISO certification for the commercialization of IMBG test 65

6.14 Dec 10, 2019: Siemens Healthineers gives details on second phase of Strategy 2025 and on the further development of its businesses 65

7 Appendix 67

7.1 Methodology 67

7.2 About GlobalData 71

7.3 Contact Us 71

List of Tables

Table 1: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Stage of Development 7

Table 2: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Territory 8

Table 3: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Regulatory Path 9

Table 4: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Estimated Approval Date 10

Table 5: Immunosuppressant Therapeutic Drug Monitoring Companies – Pipeline Products by Stage of Development 11

Table 6: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Stage of Development 12

Table 7: BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview 14

Table 8: Immunobiogram – Renal Transplantation – Product Status 14

Table 9: Immunobiogram – Renal Transplantation – Product Description 14

Table 10: Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 15

Table 11: DoseASSURE RTX Assay – Product Status 15

Table 12: DoseASSURE RTX Assay – Product Description 16

Table 13: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 17

Table 14: VITROS XT 7600 Integrated System – Cedia Cyclosporine Assay – Product Status 17

Table 15: VITROS XT 7600 Integrated System – Cedia Cyclosporine Assay – Product Description 18

Table 16: VITROS XT 7600 Integrated System – Cedia Mycophenolic Acid Assay – Product Status 18

Table 17: VITROS XT 7600 Integrated System – Cedia Mycophenolic Acid Assay – Product Description 18

Table 18: VITROS XT 7600 Integrated System – Methotrexate Assay – Product Status 19

Table 19: VITROS XT 7600 Integrated System – Methotrexate Assay – Product Description 19

Table 20: VITROS XT 7600 Integrated System – QMS Everolimus Assay – Product Status 19

Table 21: VITROS XT 7600 Integrated System – QMS Everolimus Assay – Product Description 20

Table 22: VITROS XT 7600 Integrated System – QMS Tacrolimus Assay – Product Status 20

Table 23: VITROS XT 7600 Integrated System – QMS Tacrolimus Assay – Product Description 20

Table 24: Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 21

Table 25: Promonitor – Autoimmune And Inflammation – Product Status 21

Table 26: Promonitor – Autoimmune And Inflammation – Product Description 21

Table 27: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 22

Table 28: Cobas – Cyclosporin A Assay – Product Status 23

Table 29: Cobas – Cyclosporin A Assay – Product Description 23

Table 30: Cobas 4000 Analyzer Series With e 411 Module – Cyclosporine Assay – Product Status 23

Table 31: Cobas 4000 Analyzer Series With e 411 Module – Cyclosporine Assay – Product Description 24

Table 32: Cobas 4000 Analyzer Series With e 411 Module – Tacrolimus Assay – Product Status 24

Table 33: Cobas 4000 Analyzer Series With e 411 Module – Tacrolimus Assay – Product Description 24

Table 34: Cobas 6000 Analyzer Series With c 501 Module – Cyclosporine Assay – Product Status 25

Table 35: Cobas 6000 Analyzer Series With c 501 Module – Cyclosporine Assay – Product Description 25

Table 36: Cobas 6000 Analyzer Series With c 501 Module – Everolimus Assay – Product Status 25

Table 37: Cobas 6000 Analyzer Series With c 501 Module – Everolimus Assay – Product Description 26

Table 38: Cobas 6000 Analyzer Series With c 501 Module – Sirolimus Assay – Product Status 26

Table 39: Cobas 6000 Analyzer Series With c 501 Module – Sirolimus Assay – Product Description 26

Table 40: Cobas 6000 Analyzer Series With c 501 Module – Tacrolimus Assay – Product Status 27

Table 41: Cobas 6000 Analyzer Series With c 501 Module – Tacrolimus Assay – Product Description 27

Table 42: Cobas 6000 Analyzer Series With e 601 Module – Cyclosporine Assay – Product Status 27

Table 43: Cobas 6000 Analyzer Series With e 601 Module – Cyclosporine Assay – Product Description 28

Table 44: Cobas 6000 Analyzer Series With e 601 Module – Everolimus Assay – Product Status 28

Table 45: Cobas 6000 Analyzer Series With e 601 Module – Everolimus Assay – Product Description 28

Table 46: Cobas 6000 Analyzer Series With e 601 Module – Sirolimus Assay – Product Status 29

Table 47: Cobas 6000 Analyzer Series With e 601 Module – Sirolimus Assay – Product Description 29

Table 48: Cobas 8000 Analyzer Series With c 502 Module – Everolimus Assay – Product Status 29

Table 49: Cobas 8000 Analyzer Series With c 502 Module – Everolimus Assay – Product Description 29

Table 50: Cobas 8000 Analyzer Series With c 502 Module – Sirolimus Assay – Product Status 30

Table 51: Cobas 8000 Analyzer Series With c 502 Module – Sirolimus Assay – Product Description 30

Table 52: Cobas 8000 Analyzer Series With c 502 Module – Tacrolimus Assay – Product Status 30

Table 53: Cobas 8000 Analyzer Series With c 502 Module – Tacrolimus Assay – Product Description 31

Table 54: Cobas 8000 Analyzer Series With c 701 Module – Everolimus Assay – Product Status 31

Table 55: Cobas 8000 Analyzer Series With c 701 Module – Everolimus Assay – Product Description 31

Table 56: Cobas 8000 Analyzer Series With c 701 Module – Sirolimus Assay – Product Status 32

Table 57: Cobas 8000 Analyzer Series With c 701 Module – Sirolimus Assay – Product Description 32

Table 58: Cobas 8000 Analyzer Series With c 701 Module – Tacrolimus Assay – Product Status 32

Table 59: Cobas 8000 Analyzer Series With c 701 Module – Tacrolimus Assay – Product Description 33

Table 60: Cobas 8000 Analyzer Series With c 702 Module – Everolimus Assay – Product Status 33

Table 61: Cobas 8000 Analyzer Series With c 702 Module – Everolimus Assay – Product Description 33

Table 62: Cobas 8000 Analyzer Series With c 702 Module – Sirolimus Assay – Product Status 34

Table 63: Cobas 8000 Analyzer Series With c 702 Module – Sirolimus Assay – Product Description 34

Table 64: Cobas 8000 Analyzer Series With c 702 Module – Tacrolimus Assay – Product Status 34

Table 65: Cobas 8000 Analyzer Series With c 702 Module – Tacrolimus Assay – Product Description 35

Table 66: Cobas 8000 Analyzer Series With e 602 Module – Everolimus Assay – Product Status 35

Table 67: Cobas 8000 Analyzer Series With e 602 Module – Everolimus Assay – Product Description 35

Table 68: Cobas 8000 Analyzer Series With e 801 Module – Everolimus Assay – Product Status 36

Table 69: Cobas 8000 Analyzer Series With e 801 Module – Everolimus Assay – Product Description 36

Table 70: Cobas 8000 Analyzer Series With e 801 Module – Tacrolimus Assay – Product Status 36

Table 71: Cobas 8000 Analyzer Series With e 801 Module – Tacrolimus Assay – Product Description 36

Table 72: Integrated Modular Analytics – Tacrolimus Test – Product Status 37

Table 73: Integrated Modular Analytics – Tacrolimus Test – Product Description 37

Table 74: Integrated Modular Analytics System – Mycophenolic Acid Test – Product Status 37

Table 75: Integrated Modular Analytics System – Mycophenolic Acid Test – Product Description 37

Table 76: Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38

Table 77: ADVIA Centaur CP Immunoassay System – Everolimus Assay – Product Status 38

Table 78: ADVIA Centaur CP Immunoassay System – Everolimus Assay – Product Description 39

Table 79: ADVIA Centaur CP Immunoassay System – Sirolimus Assay – Product Status 39

Table 80: ADVIA Centaur CP Immunoassay System – Sirolimus Assay – Product Description 39

Table 81: ADVIA Centaur CP Immunoassay System – Tacrolimus Assay – Product Status 40

Table 82: ADVIA Centaur CP Immunoassay System – Tacrolimus Assay – Product Description 40

Table 83: ADVIA Centaur XP Immunoassay System – Everolimus Assay – Product Status 40

Table 84: ADVIA Centaur XP Immunoassay System – Everolimus Assay – Product Description 41

Table 85: ADVIA Centaur XP Immunoassay System – Sirolimus Assay – Product Status 41

Table 86: ADVIA Centaur XP Immunoassay System – Sirolimus Assay – Product Description 41

Table 87: ADVIA Centaur XP Immunoassay System – Tacrolimus Assay – Product Status 42

Table 88: ADVIA Centaur XP Immunoassay System – Tacrolimus Assay – Product Description 42

Table 89: ADVIA Centaur XPT Immunoassay System – Everolimus Assay – Product Status 42

Table 90: ADVIA Centaur XPT Immunoassay System – Everolimus Assay – Product Description 42

Table 91: ADVIA Centaur XPT Immunoassay System – Sirolimus Assay – Product Status 43

Table 92: ADVIA Centaur XPT Immunoassay System – Sirolimus Assay – Product Description 43

Table 93: ADVIA Centaur XPT Immunoassay System – Tacrolimus Assay – Product Status 43

Table 94: ADVIA Centaur XPT Immunoassay System – Tacrolimus Assay – Product Description 43

Table 95: Atellica IM Analyzer – Everolimus Assay – Product Status 44

Table 96: Atellica IM Analyzer – Everolimus Assay – Product Description 44

Table 97: Atellica IM Analyzer – Sirolimus Assay – Product Status 44

Table 98: Atellica IM Analyzer – Sirolimus Assay – Product Description 45

Table 99: Dimension EXL 200 Integrated Chemistry System – Everolimus Assay – Product Status 45

Table 100: Dimension EXL 200 Integrated Chemistry System – Everolimus Assay – Product Description 45

Table 101: Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 46

Table 102: Cascadion SM Immunosuppressants Panel – Product Status 46

Table 103: Cascadion SM Immunosuppressants Panel – Product Description 46

Table 104: Glossary 70

List of Figures

Figure 1: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Stage of Development 7

Figure 2: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Territory 8

Figure 3: Immunosuppressant Therapeutic Drug Monitoring – Pipeline Products by Regulatory Path 9

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports